The Phase 0 clinical trials by [89Zr]Zr-DFO-daratumumab PET/CT imaging study included 10 MM patients and half of them demonstrated avidity on osseous lesions, especially one patient who demonstrated unexpected focal tracer uptake previously undetected by 18F-FDG, consistent with the lack of uptake in low CD38 expression lesions demonstrated by molecular detection approaches (listed in Table 2). This evidence concerns the gene CD38 and Miyoshi myopathy.